Colzi A, d'Agostini F, Kettler R, Borroni E, Da Prada M
Pharmaceutical Research Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
J Neural Transm Suppl. 1990;32:79-84. doi: 10.1007/978-3-7091-9113-2_9.
The effect of reversible inhibitors of the monoamine oxidase type A (MAO-A), moclobemide (Aurorix) and Ro 41-1049 (20 mg/kg i.p. each), as well as of reversible inhibitors of the MAO type B (MAO-B), Ro 19-6327 (1 mg/kg i.p.), on the outflow of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) was studied in the rat by transstriatal microdialysis. Reversible MAO-A inhibitors markedly increased the output of DA and concomitantly decreased the output of DOPAC and HVA. These effects were absent with the highly selective MAO-B inhibitor Ro 19-6327.
通过纹状体微透析法，研究了单胺氧化酶A（MAO-A）可逆性抑制剂吗氯贝胺（Aurorix）和Ro 41-1049（各20毫克/千克腹腔注射）以及单胺氧化酶B（MAO-B）可逆性抑制剂Ro 19-6327（1毫克/千克腹腔注射）对大鼠多巴胺（DA）、3,4-二羟基苯乙酸（DOPAC）和高香草酸（HVA）流出量的影响。可逆性MAO-A抑制剂显著增加了DA的流出量，同时降低了DOPAC和HVA的流出量。高选择性MAO-B抑制剂Ro 19-6327则没有这些作用。
